

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

PCT APPLICATION NO. (If known, see 37 CFR 1.5)

09/508661

INTERNATIONAL APPLICATION NO.
PCT/GB98/02899INTERNATIONAL FILING DATE
25 September 1998PRIORITY DATE CLAIMED
26 Sept 97 28 Nov 97

TITLE OF INVENTION Pharmaceutical Composition for the Treatment of Inflammatory Bowel Disease

APPLICANT(S) FOR DO/EO/US

SACHETTO, Jean-Pierre SANDBORN, William Jeffrey TREMAINE William John

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

17. ☒ The following fees are submitted:

422 Rec'd PCT/PTO 2 2 MAR 2000

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	22 - 20 =	2	X \$18.00
Independent claims	4 - 3 =	1	X \$78.00

\$ 36.00

\$ 78.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$260.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 1084.00

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 1084.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 1084.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property -

\$

TOTAL FEES ENCLOSED =

\$ 1084.00

Amount to be refunded:	\$
charged:	\$

a. ☒ A check in the amount of \$ 1084.00 to cover the above fees is enclosed

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 10-1213. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

James W. Hellwege
Jones, Tullar & Cooper, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703-415-1500 (tel)
703-415-1508 (fax)

SIGNATURE

James W. Hellwege

NAME

28,808

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Sachetto et al

National Stage application of
PCT/GB98/02899

Filed: March 23, 2000

For: PHARMACEUTICAL COMPOSITION FOR THE
TREATMENT OF INFLAMMATORY BOWEL DISEASE

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination of the above application, please amend the application as follows:

IN THE CLAIMS:

Cancel claims 16-21.

Amend the claims as follows:

1. (Amended) A rectally administrable or post-gastrically available delayed release oral (DRO) or [rectally administrable] pharmaceutical composition for the treatment or prophylaxis of inflammatory bowel disease (IBD), said composition comprising a

polysaccharide selected from xanthan gum and hydroxypropylmethylcellulose (HPMC) as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.

2. (Amended) [A] The composition [as claimed in] according to Claim 1, wherein the polysaccharide is xanthan gum.

3. (Amended) [A] The composition [as claimed in] according to Claim 1, wherein the polysaccharide is HPMC.

4. (Amended) [A] The composition [as claimed in] according to [any one of the preceding claims] Claim 1, wherein the polysaccharide is present as the sole therapeutically active ingredient.

5. (Amended) [A] The [DRO] composition [as claimed in] according to [any one of the preceding claims] Claim 1 which is a DRO composition.

6. (Amended) [A] The [DRO] composition [as claimed in] according to Claim 5 which DRO composition is an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.

7. (Amended) [A] The rectally administrable composition [as claimed in]
according to [any one of Claims 1 to 4] Claim 1.

8. (Amended) [A] The rectally administrable composition [as claimed in]
according to Claim 7 which is a liquid enema or foam enema.

9. (Amended) [A] The [liquid enema] composition [as claimed in] according to
Claim [8] 2, which is a liquid enema containing [wherein the polysaccharide is] xanthan
gum in a concentration of about 0.4 to about 2% w/w (based on the composition).

10. (Amended) [A] The [foam enema] composition [as claimed in] according to
Claim [8] 2, which is a foam enema containing [wherein the polysaccharide is] xanthan
gum in a concentration of about 1.4 to about 2.5 % w/w (based on the composition).

11. (Amended) [A] The [liquid enema] composition [as claimed in] according to
Claim [8] 3, which is a liquid enema containing [wherein the polysaccharide is] HPMC in
a concentration of about 1 to about 20 % w/w (based on the composition).

12. (Amended) [A] The [foam enema] composition [as claimed in] according to
Claim [8] 3, which is a foam enema containing [wherein the polysaccharide is] HPMC in
a concentration of about 2.5 to about 25% w/w (based on the composition).

13. (Amended) [A] The rectally administrable composition [as claimed in] according to Claim 7 [or Claim 8], wherein the polysaccharide is xanthan gum in an amount of about 400 to about 2000 mg per unit dose.

14. (Amended) [A] The rectally administrable composition [as claimed in] according to Claim 7 [or Claim 8], wherein the polysaccharide is HPMC in an amount of about 1 to about 20 g per unit dose.

15. (Amended) [A] The DRO composition [as claimed in] according to Claim 5 [or Claim 6, wherein the] in unit dose form containing about 400 to about 2000 mg of the polysaccharide [is 400 to 2000 mg] per unit dose.

22. (Amended) A method for the treatment or prophylaxis of inflammatory bowel disease (IBD) comprising contacting the diseased mucosa of the gastro-intestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and hydroxypropylmethylcellulose (HPMC).

Add the following new claims:

- - 23. The liquid enema according to Claim 11, wherein the HPMC is in a concentration of 5 to 20 % w/w (based on the composition).

24. The method according to Claim 22 wherein the disease state is pouchitis.

25. The method according to Claim 22 wherein the disease state is left-sided ulcerative colitis.

26. The method according to Claim 22 wherein the disease state is Crohn's disease.

27. A liquid enema for the treatment or prophylaxis of inflammatory bowel disease (IBD) comprising xanthan gum in a concentration of about 0.4 to about 2 % w/w (based on the composition) as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.


28. A foam enema for the treatment or prophylaxis of inflammatory bowel disease (IBD) comprising xanthan gum in a concentration of about 1.4 to 2.5 % w/w (based on the composition) as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle. - -

REMARKS

The claims are amended to place same in a form suitable for examination. No new matter is added by this amendment.

Respectfully submitted,

BY:


James W. Hellwege
Registration No. 28,808

Jones, Tullar & Cooper, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703-415-1500
Filed: March 22, 2000

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT
OF INFLAMMATORY BOWEL DISEASE

This invention relates to use of xanthan gum or
5 hydroxypropylmethylcellulose (HPMC), particularly in the
form of enemas for the treatment of inflammatory bowel
disease (IBD), and to orally administrable and
rectally/vaginally administrable compositions containing
xanthan gum or HPMC as a therapeutically active agent.

10 Xanthan gum (CAS registry no. 1138-66-2) is described
in USP NF XVI (p161) as a high molecular weight
polysaccharide gum produced by a pure-culture fermentation
of a carbohydrate with Xanthomonas campestris. It contains
15 D-glucose and D-mannose as the dominant hexose units, along
with D-glucuronic acid and is prepared as the sodium,
potassium or calcium salt. It is widely used in
pharmaceutical compositions as an emulsifying, stabilising
and/or thickening agent.

20 HPMC (CAS registry no. 9004-65-3), otherwise known as
hypromellose, is used as a suspending agent, tablet
excipient, demulcent and/or viscosity increasing agent in
pharmaceutical compositions. It is been used as a capsule
25 or tablet coating, but the coating is soluble in gastric
juices, and so would deliver the active in the capsule in
the stomach.

30 IBD covers chronic non-specific inflammatory conditions
of the gastro-intestinal tract, of which the two major forms
are Crohn's disease and ulcerative colitis. The aetiology
of these diseases is uncertain. Many inflammatory mediators
have been proposed including prostanoids, leukotrienes,
platelet activating factor, cytokines, and free oxygen
35 radicals. Although specific inhibitors of most of these
have been tried in experimental models, the most effective
drugs currently available for these diseases have a broad
activity against inflammatory processes.

Crohn's disease is characterised by thickened areas of the gastro-intestinal wall, with inflammation extending through all layers, deep ulceration and fissuring of the mucosa, and the presence of granulomas. Affected areas may occur in any part of the gastro-intestinal tract, although the terminal ileum is frequently involved, and they may be interspersed with areas of relatively normal tissue. Fistulas and abscesses may develop. Symptoms depend on the site of disease but may include abdominal pain, diarrhoea, fever, weight loss and rectal bleeding.

In ulcerative colitis, disease is continued to the colon and rectum. Inflammation is superficial but continuous over the affected area and granulomas are rare. In mild disease, the rectum alone may be affected (proctitis). In severe disease ulceration is extensive and much of the mucosa may be lost, with an increased risk of toxic dilatation of the colon, a potentially life-threatening complication.

Abdominal colectomy with mucosal proctectomy and ileal pouch-anal anastomosis is the preferred treatment for most patients with ulcerative colitis who require surgery. Pouchitis, the most common long-term complication of the procedure, occurs in up to 49% of patients at 10 years. Chronic pouchitis is distinguished from acute pouchitis by duration of symptoms for more than 4 weeks. The aetiology of pouchitis is unknown but it appears that both a history of ulcerative colitis and increased bacterial concentrations (relative to the normal ileum) are factors.

Currently, there is no satisfactory treatment for patients with chronic pouchitis who fail to respond to empiric antibiotic therapy. Although metronidazole is effective in some patients, long-term use is limited by concerns for neurotoxicity with peripheral neuropathy.

Numerous compounds have been examined in the last twenty years to find effective measures for the treatment of IBD. Such compounds include azathioprine, arsenicals, disodium cromoglycate, metronidazole, lignocaine, 5-aminosalicylic acid (5-ASA), fish oils, thalidomide and cyclosporin. The wide diversity of treatments, is an indication of the complexity and intransigence of IBD.

GB-A-1538123 (published 8th January 1979) disclosed the treatment of diverticulitis with a fibrous cellulosic material and a carboxylic polymer or salt which absorbs water and swells above pH 4. Specified carboxylic polymers include sodium carboxymethylcellulose (sodium CMC).

EP-A-0351987 (published 24th January 1990) disclosed the use of a polyacrylate, preferably a carbomer, for the treatment of IBD by oral or rectal administration.

US-A-4917890 (published 17th April 1990) disclosed the treatment of ulcerative colitis with a mucilaginous polysaccharide aloe extract.

WO-A-94/01436 (published 3rd March 1994; corresponding to US-A-5380522) disclosed treatment of irritable bowel syndrome (IBS) with an oral medicament of an anion-binding polymer and a hydrophilic polymer. Exemplified anion-binding polymers include xanthan gum.

WO-A-9407540 (published 14th April 1994; corresponding to EP-A-0620012 & US-A-5518711) disclosed an X-ray contrast medium containing 15-35 w/v% BaSO₄ and 0.15-0.6 w/v% xanthan gum dispersed in water. Lower xanthan gum concentrations are used with higher BaSO₄ concentrations. The medium is useful for double contrast enema examination of the large and the small intestine to detect *inter alia* Crohn's disease.

Sandborn et al (Gastroenterology 1994, 106, 1429-1435) reported a placebo-controlled trial of cyclosporin enemas in the treatment of mildly to moderately active left-sided ulcerative colitis. The vehicle for both the test and
5 placebo enemas comprised 60 cm³ water, 5 mg sorbitol (to make the vehicle isomolar) and 500 mg carboxymethylcellulose (CMC) (to suspend the hydrophobic cyclosporin). The placebo enema contained 3.5 cm³ olive oil and use of this enema resulted in clinical improvement in nine out of twenty
10 patients tested.

WO-A-9603115 (published 8th February 1996) disclosed aqueous foamable compositions having a delayed foaming action on expulsion from a pressurised container, comprising
15 a water-immiscible liquefied gas, a water soluble polymer, and optionally, *inter alia*, a muco-adhesive agent. Exemplified water-soluble polymers include xanthan gum and HPMC and exemplified muco-adhesive agents include CMC. The compositions are of particular use for rectal or vaginal
20 administration of pharmaceuticals to treat *inter alia* ulcerative colitis or Crohn's disease.

JP-A-08198757 (published 6th August 1996) discloses the use of high amylose starch, preferably administered with
25 food materials, for the treatment of chronic ulcerative colitis.

The present Inventors found that xanthan gum and HPMC are effective *per se* for the treatment of IBD. This is
30 surprising because, as indicated above, these materials are widely used in pharmaceutical compositions because of their assumed lack of pharmacological activity.

WO 98/01112 (published 15th January 1998; after the
35 claimed priority dates of the present Application) discloses the treatment of distal IBD with a hydrogel formulation consisting essentially of a gelling agent and water with the optional presence of a pH-adjusting agent, plasticizer

009250 19990504

and/or surfactant. The preferred gelling agents include HPMC and sodium CMC. The only specified distal IBD is ulcerative colitis.

5 According to a first aspect of the present invention, there is provided the use of a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.

10

By IBD we mean Crohn's Disease and ulcerative colitis including ulcerative proctitis, ulcerative proctosigmoiditis, lymphocytic colitis, intractable distal colitis, ileocolitis, collagenous colitis, microscopic colitis, pouchitis, radiation colitis, and antibiotic-associated colitis. Xanthane gum and HPMC have been found to be particularly useful in the treatment of IBD conditions (such as pouchitis and left-sided ulcerative colitis) normally refractive to conventional therapy.

20

In a second aspect, the present invention provides a post-gastrically available delayed release oral (DRO) or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in an amount effective to treat IBD, together with a pharmaceutically acceptable carrier or vehicle. DRO compositions pass through the stomach substantially unaltered and deliver their active ingredient (which is within the tablet, capsule etc.) typically to the ileum up to and including the colon (i.e. where the diseased mucosa is).

According to a third aspect, the present invention provides a post-gastrically available DRO or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as the

sole therapeutically active agent together with a pharmaceutically acceptable carrier or vehicle.

In a fourth aspect, the present invention provides the use of a polysaccharide selected from xanthan gum and HPMC as the sole therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.

In yet another aspect of the present invention, there is provided a method for the treatment or prophylaxis of IBD comprising contacting the diseased mucosa of the gastrointestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and HPMC.

The polysaccharide can be used in the form of pharmaceutically acceptable salts of such as with alkali metals, usually sodium or potassium and alkaline earth metals, usually calcium or barium.

When the polysaccharide is present as the sole active agent, then no other therapeutically active agent such as 5-ASA or a corticosteroid will be present. Optionally, however, other therapeutic agents currently used or proposed for treating IBD can also be used sequentially in a different dosage form or concomitantly in the same dosage form as the polysaccharide. Examples of other such therapeutic agents are 5-ASA; immune modifiers such as azathioprine, cyclosporin and FK506; corticosteroids such as prednisolone, budesonide and hydrocortisone; antibiotics such as metronidazole, ciprofloxacin, amoxicillin, tetracycline and sulphamethoxazole; antidiarrheals such as loperamide and codeine sulphate; and local anaesthetics such as lignocaine.

The polysaccharide may be incorporated into a pharmaceutical composition to be administered either rectally, e.g. as an enema, or orally, for example, in coated tablets or capsules as described below. Also, the

polysaccharide may be formed into microgranules and coated, for example with Eudragit™ L or S and contained within a capsule similarly coated. In all solid compositions, it is preferable to include a disintegrant. Still further, the
5 polysaccharide may be formulated in a number of dosage forms, e.g. uncoated or coated solid dosage forms for delayed release oral administration, for example using polymers in the Eudragit™ product range.

10 According to a preferred embodiment of the present invention, the pharmaceutical composition takes the form of an enema formulation such as a liquid or foam enema which is rectally administered to the lower colon. The enema
15 formulations suitably comprise the polysaccharide dissolved or dispersed in a suitable flowable carrier vehicle, such as deionised and/or distilled water. The formulation can be thickened with one or more thickeners, can contain a buffer, and can also comprise an effective amount of a lubricant
20 such as a natural or synthetic fat or oil, e.g. a tris-fatty acid glycerate or lecithin. Non-toxic non-ionic surfactants can also be included as wetting agents and dispersants. Unit doses of enema formulations can be administered from pre-filled bags or syringes. In the case of a pressurised
25 enema formulation the carrier vehicle may also comprise an effective amount of a foaming agent such as *n*-butane, propane or *i*-butane, or the foaming agent/propellant could be held separately from the composition such as in a bag-in-bag or bag-in-can system as described in WO-A-9603115
(incorporated herein by reference). Enema foams may also
30 comprise expanding agents and foam-stabilisers.

The viscosity of the enema is preferably 10,000 to 70,000 mPa.s more preferably 10,000 to 70,000 mPa.s and most preferably 10,000 to 40,000 mPa.s. The pH is preferably 3.5
35 to 7.5, especially 6.5 to 7.5.

A suitable dosage for xanthan gum in an enema or foam enema is 200 to 2000 mg, preferably 250 to 2000 mg, more

009250 1000000

preferably 250 to 1650 mg, more preferably still 400 to 1650 mg, especially 550 to 1000 mg, in an aqueous or non-aqueous carrier. The volume of a liquid enema is typically 50 to 200 cm³ preferably about 100 cm³. A suitable % w/w of xanthan gum in an enema is (based on 100 cm³ enema) is 0.2% to 2% w/w, more preferably 0.3% to 2% w/w, more preferably still 0.4% to 2% w/w, more preferably still up to 1.65% w/w, and still more preferably 0.55% to 1%. Suitably the volume of a foam enema is 20 to 40 cm³. Based on the above preferred dosages, a suitable % w/w of xanthan gum in a foam enema (based on 40 cm³ foam enema) is 1% to 4.25% w/w, more preferably 1.4% to 2.5%. A buffer is preferably added to the liquid or foam enema of xanthan gum to stabilise the pH. When a buffer is used it increases the viscosity and as a result, the maximum % w/w of xanthan gum that can be incorporated in the enema is about 1.7% w/w.

Typically the viscosity grade of xanthan gum used in a rectally administrable or DRO composition of the invention is 1,200 to 1,600 cP (mPa.s) at 1%.

Typically the viscosity grade of HPMC used in a rectally administrable or DRO composition of the invention is 3 to 100,000 cP (mPa.s). More particularly the grade of HPMC varies depending on the degree of hydroxypropoxy and methoxy substitution. Thus, preferably the degree of methoxy substitution is 15 to 30%, more preferably 19 to 30% such as 19 to 24% and 27 or 28 to 30%. The degree of hydroxypropoxy substitution is preferably 2 to 15%, more preferably 4 to 12%, such as 7 to 12% or 4 to 7.5%. The commercially available grades of HPMC include the following:

Product	% Methoxyl	% Hydroxypropoxyl	Viscosity cP (Mpa.s)	Relative Rate of Hydration
METHOCEL™ K Premium	19-24	7-12	3, 100, 4000, 15000, 100000	Fastest
METHOCEL™ E Premium	28-30	7-12	3, 5, 6, 15, 50, 4000	Next fastest
METHOCEL™ F Premium	27-30	4-7.5	50, 4000	Slower

The large range of viscosities allows a high dosage
 liquid enema or foam enema of HPMC to be formed by using a
 5 low viscosity grade of HPMC (i.e. a higher dosage than
 xanthan gum can be incorporated since the viscosity of the
 HPMC is less limiting). A suitable dosage of HPMC for a
 liquid enema or foam enema is 0.2 to 20 g, preferably 1 to
 20g, more preferably 2 to 10 g, still more preferably 5 to
 10 10 g for some IBD disease states and 1 to 5 g for other IBD
 disease states. A suitable % w/w of HPMC in a liquid enema
 or foam enema (based on 100 cm³) is 0.2% to 20% w/w,
 preferably 1% or 2% w/w to 20%, more preferably to an upper
 limit of 10% w/w, more preferably still 5% to 10%. A
 15 suitable % w/w of HPMC in a foam enema (at 40 cm³) is 1% to
 50% w/w, more preferably 2.5% to 25% w/w, such as at least
 7.5% w/w.

In a further embodiment of the invention, the
 20 polysaccharide is administered to the small intestine or
 colon of a patient by oral ingestion of a post-gastric
 delayed release (DRO) unit dosage form such as a tablet or
 capsule, comprising an effective amount of polysaccharide
 which is enterically coated so as to be released from the
 25 unit dosage form in the lower intestinal tract, e.g. in the

ileum and/or in the colon of the patient. Enteric coatings remain intact in the stomach, but dissolve and release the contents of the dosage form once it reaches the region where the pH is optimal for dissolution for the coating used.

5

A DRO formulation can also be achieved by coating a powder or microgranular formulation of the polysaccharide with coatings as mentioned above. The coated microgranules or material may then be compressed into tablets or packed into hard gelatin capsules suitable for oral administration. Suitable coatings and thicknesses to achieve this sustained release are disclosed in EP-A-0572486 (incorporated herein by reference).

The DRO form may optionally also be formulated to give a sustained release of the polysaccharide. The delayed release can be obtained, for example, by complexing the polysaccharide with a polyacrylic acid derivative (a polysaccharide polyacrylate complex) more particularly a polysaccharide carbomer complex. Alternatively particles of the polysaccharide complex could be incorporated into a hydrophobic matrix such as Gelucire™ (Gattefosse, France).

Aqueous film-coating technology is advantageously employed for the enteric coating of pharmaceutical dosage forms. A useful enteric coating is one that remains intact in the low pH of the stomach, but readily dissolves when the optimum dissolution pH of the particular coating is reached. This can vary between pH 3 to 7.5, preferably pH 5 to 7, most preferably pH 5.5 to 6.8, depending on the chemical composition of the enteric coating. The thickness of the coating will depend on the solubility characteristics of the coating material and the site to be treated.

By "delayed release" we mean that release is substantially post-gastrically and by "sustained release" we mean that the total release of the polysaccharide is slow

and sustained over a period of time, as opposed to being released as a bolus.

The majority of the release will be targeted to the part of the small intestine or colon where the active disease is prevalent and this varies for Crohn's disease and ulcerative colitis. Thus typically for an enteric coated capsule, the enteric coating should dissolve in the pH of the jejunum (about pH 5.5), ileum (about pH 6) or colon (about pH 6-7) so as to release the majority of the active from the jejunum to the colon - where most of the active disease is located in IBD. More particularly in the case of Crohn's disease most of the active disease is around the terminal ileum and so the enteric coating should dissolve about pH 5.5 to 6. In the case of ulcerative colitis, the disease is mostly in the colon and therefore the enteric coating should dissolve about pH 6 to 7, more particularly about pH 6.8.

Suitably the unit dosage of the polysaccharide in the delayed release oral composition is 200 to 2000 mg, preferably 250 to 2000 mg, more preferably 250 to 1650 mg, more preferably still 400 to 1650 mg, especially 550 to 1000 mg. A suitable % w/w of the polysaccharide in a DRO of the invention is 40 to 90% w/w, more preferably 60 to 80% w/w.

The above also is approximate to the total daily dosage and can be achieved by one or more unit dosages taken once, twice, three or more times daily. For example the total daily dosage is typically 200 to 6000 mg, preferably having an upper dosage limit of about 4000 mg and a lower limit of about 400 mg.

The DRO formulation can be provided as an enteric coated capsule containing the polysaccharide and having a coating thickness and dissolution profile as described in EP-A-0097651 (the contents of which are incorporated herein by reference). Suitable coating include cellulose acetate

phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose or polyvinyl acetate phthalate but the preferred coating material is an anionic polymer, especially one having the dissolution profile specified in EP-A-0097651, optionally in admixture with a neutral insoluble but permeable polymer. The presently preferred anionic polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the anionic polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers such as poly(methacrylic acid, methyl methacrylate) in which the ratio of free acid groups to ester groups is about 1:1 (e.g. those available from Röhm Pharma GmbH under the Trade Mark EUDRAGIT S). A neutral polymer coating, more specifically poly(ethylacrylate-methylmethacrylate) (e.g. Eudragit™ NE30D) may also be useful in some instances.

Examples of methacrylates (in the Eudragit™ range) for use as enteric coatings in accordance with the invention are as follows.

Chemical name	Trade name	CAS number
Poly(methacrylic acid, methyl methacrylate) 1:1	Eudragit™ L 100 Eudragit™ L 12.5 Euragit™ L 12.5 P	[25806-15-1]
Poly(methacrylic acid, ethyl acrylate) 1:1	Eudragit™ L 30 D-55 Eudragit™ L 100-55	[25212-88-8]
Poly(methacrylic acid, methyl methacrylate) 1:2	Eudragit™ S 100 Eudragit™ S 12.5 Eudragit™ S 12.5 P	[25086-15-1]

In general coating thicknesses of about 25 to 200 μm , and especially 75 to 150 μm , are preferred using about 3 to 25 mg, preferably 8 to 15 mg of acidic coating material per

cm² of tablet or capsule surface. The precise coating thickness will however depend upon the solubility characteristics of the acidic material used and site to be treated.

5

In another preferred DRO or rectally administrable embodiment of the invention, sub 150µm particles of the polysaccharide or complex thereof (e.g. carbomer complex) is coated (partially or completely) or impregnated with a water insoluble anionic polymer. This prevents the formation of lumps and encourages the resulting hydrophobic particles of polysaccharide to disperse and coat the bowel wall when the contents of the DRO tablet or capsule are released. This technology is described in more detail in International Patent Application no. PCT/GB97/01847 (WO-A-9802573) (incorporated herein by reference).

By "sub 150µm particles", we mean such that 100% of particles in the DRO will pass through a 150 µm sieve. It is preferred that 100% of the hydrophilic carbomer particles pass a 100 µm sieve screen (i.e. they are sub 100 µm), more preferably at least 90%, especially at least 95%, of the hydrophilic particles pass a 63 µm sieve screen, more preferably a 50 µm sieve screen. The precise particle size must be small enough to provide a composition with a suitable degree of hydrophobicity following coating with the anionic polymer. Preferred particle size may vary according to the nature and amount of the cation present in the complex and the nature and amount of the anionic polymer.

30

The amount of anionic polymer used will depend upon the nature and amount of the cation present in the salt, the nature of the impregnating anionic polymer, and the degree of hydrophobicity required. A suitable amount can be determined by simple experimentation but usually the anionic polymer will be present in an amount of 10 to 50%, preferably 20 to 40, more preferably 25 to 35 and especially about one third, based on the weight of the carbomer

35

09500661.00000

complex. Having regard to the small particle size, the amount of polymer will be less than the theoretical amount required to coat the particles, and the swelling and dissolution of the carbomer will not be controlled by pH.

5

The polysaccharide particles are impregnated/hydrophobised by milling and passing through a suitable sieve (as aforementioned), stirring the sieved particles into a mixture of e.g. isopropanol and water (solvent) and partly methyl esterified methacrylic acid polymer (e.g. Eudragit™ S100) at from 20 to 40% by weight of the polysaccharide particles (the solvent/coating solution having previously been agitated until clear), stirring and then evaporating the solvent under vacuum at about 50-70 °C to leave coated polysaccharide particles. Thereafter the resulting powder can be filled into gelatin capsules ready for enteric coating.

The invention will now be described by way of the following Examples.

Example 1 : Enema with HPMC.

947.6 g of purified water is preserved with 2 g of methyl and 0.4 g propyl parabens. 50 g (dry basis) of HPMC (Methocel E) low viscosity grade (50 cP/mPa.s) is dissolved under mechanical stirring at room temperature. The solution is degassed (air) under reduced pressure in an oven. A clear viscous enema is obtained having pH 6.9, viscosity (spindle 64, 1.5 rpm - 20°C on Brookfield DV 11): 4,000 mPa.s. The formation is packed in a bag-in-can canister or in an enema plastic pouch or in a PE bottle all having a 100 g enema capacity delivery, thus delivering a full dose of 5,000 mg HPMC.

Example 2 : Foam Enema Formulation with Xanthan Gum.

14,871 g of purified water containing 22 g of dissolved methyl paraben and 2 g of dissolved propyl paraben as preservatives were placed in a 20 litre Moltomat-Universal™ MMU 20 homogenizer. Then 435g of xanthan gum (Keltrol™ TF) having a water content of 7.6% were dispersed in the preserved water under efficient homogenization and reduced pressure.

30 g of unbleached lecithin were then added and dispersed under homogenization and reduced pressure. At this stage the pH of the viscous gel obtained was 6.3. A solution then made of 0.45 g sodium hydroxide pellets and 20 g of water was added and dispersed under reduced pressure. The pH then was 6.93. Finally 155 g of Polysorbate 80 (non-ionic surfactant) and 4 g of Citral (perfume) were added and dispersed under reduced pressure.

The final foam enema appeared as a slightly hazy gel, having a pH of 7.04 and a viscosity of 40,000 mPa.s at 20°C as measured using a Brookfield DV II viscometer (1.5 rpm, spindle 63).

A foam enema was then produced using this formulation by adding 2.2 g of n-butane per 100 g of the above formulation in a pressurised mixing unit and the mixture was then filled into bag-in-can aerosol canisters. Each canister contained 23 g of the mixture from which 21 g of foam was delivered through a valve and an applicator, i.e. about 530 mg of xanthan gum per delivered dose.

Example 3 : Liquid Enema Formulation with Xanthan Gum.

To 4,906 g of purified water containing 10 g of dissolved methyl paraben and 2 g of dissolved propyl paraben used as preservatives, 58.95 g of xanthan gum (Keltrol™ TF) containing 6.7% water (i.e. 55 g dry basis) was added in an

homogenizer and dispersed under efficient homogenization under reduced pressure. The pH of the gel obtained was 6.05 and the viscosity was 7,500 mPa.s (22°C, 1.5 rpm-spindle 63 Brookfield DV II). At this stage 23 g of sodium citrate.

- 5 2H₂O was added as buffering agent. The pH went up to 7.15 and the viscosity was 40,000 mPa.s (measured as above). The formulation, which appears as a slightly hazy gel, was then packed into a bag-in-can canister equipped with a valve and an applicator and pressurised with nitrogen. If the bag of
- 10 the bag-in-can system is filled with 104 g of the formulation above then 100 g of the formulation can be delivered through the valve and applicator corresponding to a dose of 1.1 g of xanthan gum.

15 Example 4 : Treatment of Chronic Pouchitis

- The enema of Example 2 was given to twenty adult patients who had previously undergone total colectomy with mucosal proctectomy and ileal J-pouch anal anastomosis for
- 20 ulcerative colitis and who had active chronic pouchitis refractory to standard therapy. The patients had chronic pouchitis, as defined as continuous symptoms of pouchitis for more than 4 weeks and a Pouchitis Disease Activity Index (PDAI) score of at least 7 points on an 18 point scale. All
- 25 patients had either failed or were intolerant to metronidazole as well as other commonly used treatments for pouchitis. Mucosal inflammation, determined by endoscopic examination, was limited to the pouch and did not extend into the ileum proximal to the pouch.

30

- The demographics of the patients entered into the study are presented in Table 1. There were no significant differences in the age, gender distribution, smoking history, time since the diagnosis of ulcerative colitis,
- 35 duration of pouch function, time since the first episode of pouchitis, duration of the current episode of pouchitis, or in the medications previously used for treatment of pouchitis. All patients had been on medication for

09508661.152600

pouchitis, previously, and one half of the patients were on concurrent treatment for chronic pouchitis (Table 2).

Three patients had to discontinue treatment because of
5 worsening of symptoms, but none developed dehydration or
required hospitalization. Three patients had cramping
discomfort in the pouch after taking the enema. One of the
patients who developed cramps discontinued treatment because
of the discomfort. One patient developed right lower
10 abdominal pain and the study medication was discontinued.

The initial or final endoscopic or histologic scores of
the patients are shown in Table 3.

TABLE 1

PATIENT CHARACTERISTICS

Number of Patients	20
Age (mean)	40 (18-62)
Number of Men:Women	12:8
Number of Cigarette Smokers, current:former:never	1:2:17
Years since diagnosis of Ulcerative colitis. Median (range)	9 (3-32)
Months of pouch function. Median (range)	45 (4-161)
Months since the first episode of pouchitis. Median (range)	42 (3-151)
Months of current pouchitis episode. Median (range)	4 (0.8-151)

009250 19980560

TABLE 2**THERAPY FOR POUCHITIS (20 PATIENTS)**

Therapy	No. Of Patients	
	Current	Previous
Antibiotics		
Metronidazole	3	16
Ciprofloxacin	6	15
Amoxicillin/clavulanic acid	1	6
Tetracycline	0	3
Trimethoprine/sulfamethoxazole	1	0
5-ASA		
Sulfasalazine	1	5
Oral mesalamine	0	5
Mesalamine enemas	0	3
Mesalamine suppositories	0	3
Corticosteroids		
Prednisone	1	7
Hydrocortisone enemas	0	5
Immune Modifiers		
Azathioprine	0	0
Cyclosporine	0	0
FK506	0	0
Antidiarrheals		
Loperamide	5	3
Codeine sulfate	0	1

09500667 000000

TABLE 3DISEASE ACTIVITY AT BASELINE AND COMPLETION OF TREATMENT
WITH XANTHAN GUM ENEMA

	Baseline Median (range)	Completion Median (range)
Clinical Score	4 (1,5)	3 (0,4) *
Endoscopy Score	5 (1,6)	4 (1,6)
Histology Score	2 (2,6)	# 2 (2,6)
Total Score (PDAI)	11 (7,16)	9 (2,16) *

* $p < 0.5$ for within-group change. Baseline vs completion (signed rank test with two missing values at completion filled in by overall (groups) Baseline values).

In conclusion, six of the twenty patients discontinued therapy and nine of fourteen patients (64%) who completed the treatment improved (defined as a reduction in the PDAI score of 3 points or more). This is particularly surprising in view of the fact that the patients were refractory to conventional therapy.

CLAIMS

422 Rec'd PCT/PTO 22 MAR 2000

1. A post-gastrically available delayed release oral (DRO) or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.

2. A composition as claimed in Claim 1, wherein the polysaccharide is xanthan gum.

3. A composition as claimed in Claim 1, wherein the polysaccharide is HPMC

4. A composition as claimed in any one of the preceding claims, wherein the polysaccharide is present as the sole therapeutically active ingredient.

5. A DRO composition as claimed in any one of the preceding claims.

6. A DRO composition as claimed in Claim 5 which is an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.

7. A rectally administrable composition as claimed in any one of Claims 1 to 4.

8. A rectally administrable composition as claimed in Claim 7 which is a liquid enema or foam enema.

9. A liquid enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 0.4 to 2 % w/w.

Rec'd PCT/PTO 22 MAR 2000

10. A foam enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 1.4 to 2.5 w/w.
11. A liquid enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 1 to 20 % w/w.
12. A foam enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 2.5 to 25 % w/w.
13. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is xanthan gum in an amount of 400 to 2000 mg per unit dose.
14. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is HPMC in an amount of 1 to 20 g per unit dose..
15. A DRO composition as claimed in Claim 5 or Claim 6, wherein the unit dose of the polysaccharide is 400 to 2000 mg.
16. The use of a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.
17. A use as claimed in Claim 16, wherein the polysaccharide is the sole therapeutically active agent in the medicament.
18. A use as claimed in Claim 16 or Claim 17 wherein the disease state is pouchitis.
19. A use as claimed in Claim 16 or Claim 17 wherein the disease state is left-sided ulcerative colitis.

422 Rec'd PCT/PTO 22 MAR 2000

20. A use as claimed in Claim 16 or Claim 17 wherein the disease state is Crohn's Disease.

21. A use as claimed in any one of Claims 16 to 20, wherein
5 the medicament is a composition as defined in any one of Claims 1 to 15.

22. A method for the treatment or prophylaxis of IBD
comprising contacting the diseased mucosa of the gastro-
10 intestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and HPMC.

09/508661-052600

2005年12月

This declaration is of the following type:

- My residence, post office address and citizenship are as stated next to my name.

"Pharmaceutical Composition For The Treatment Of Inflammatory Bowel Disease"

[] is attached hereto
[] was filed on _____, as
Application Serial No. _____
and was amended on _____
(if applicable)

- I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any Amendment referred to above.

§ 1.56.

- I hereby claim foreign priority benefits under Title 35, United States Code, § 119, of any foreign application(s) for patent or

inventor's certificate listed below and have also identified below any foreign application for patent of inventor's certificate having a filing date before that of the application on which priority is claimed:

[] no such applications have been filed
[X] such applications have been filed as follows.

Prior Foreign Application(s)

9720590.0	GB	26th September 1997	[]	[]
(Number)	(Country)	(day/month/year filed)	Yes	No

9725346.2	GB	28th November 1997	[]	[]
(Number)	(Country)	(day/month/year filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, § 119 (e) of any United States provisional application(s) listed below:

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose all information known to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

_____ (Application Serial No.)	_____ (Filing Date)	_____ (patented, pending, abandoned)
-----------------------------------	------------------------	--------------------------------------------

_____ (Application Serial No.)	_____ (Filing Date)	_____ (patented, pending, abandoned)
-----------------------------------	------------------------	--------------------------------------------

9

Eric S. Spector, Reg. No. 22,495
Douglas R. Hanscom, Reg. No. 26,600
William A. Blake, Reg. No. 30,548
Colin D. Barnitz, Reg. No. 35,061

Direct telephone calls to:

James W. Hellwege
(703) 415-1500

Figure 1 consists of 12 micrographs arranged in a 3x4 grid, showing the development of a single embryo from fertilization to hatching. The first row shows the fertilized egg and early cleavage stages. The second row shows the embryo with a visible yolk and developing structures. The third row shows the embryo with a prominent yolk and a developing head. The final image shows the hatched embryo with a fully formed head and tail.

I hereby declare all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor:

Jean-Pierre SACHETTO

Inventor's signature

JPSachetto

MAY 9, 2000 (Date)

Residence:

Basel, Switzerland

CHX

Citizenship:

French

Post Office Address: Duchelweiher 13, CH-4051 Basel, Switzerland.

CH-4144 ARLESHEIM

Full name of second joint inventor:

William Jeffery SANDBORN

Inventor's signature

Minnesota, US

MN

(Date)

Residence:

Citizenship:

US

Post Office Address: 1132 - 7th Street, S.W. Rochester, Minnesota 55902, USA.

Full name of third joint inventor:

William John TREMAINE

Inventor's signature

Minnesota, US

MN

(Date)

Residence:

Citizenship:

US

Post Office Address: 625 Memorial Pkwy., S.W. Rochester, Minnesota 55905, USA.

Full name of fourth joint inventor, if any

Inventor's signature

(Date)

Residence

Citizenship

Post Office Address

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

This declaration is of the following type:

- ☐ original
- ☐ design
- ☐ supplemental
- ☒ national stage of PCT
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (CIP)

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed for and for which a patent is sought on the invention entitled:

"Pharmaceutical Composition For The Treatment Of Inflammatory Bowel Disease"

the specification of which

- ☐ is attached hereto
- ☐ was filed on _____, as
Application Serial No. _____
and was amended on _____
(if applicable)

- ☒ was described and claimed in PCT International application No. **PCT/GB98/02899** filed on **25th September 1998** and as amended under PCT Article 19 on **22nd March 2000** (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any Amendment referred to above.

I acknowledge duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations,

§ 1.56.

- ☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.97.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119, of any foreign application(s) for patent or

inventor's certificate listed below and have also identified below any foreign application for patent of inventor's certificate having a filing date before that of the application on which priority is claimed:

[] no such applications have been filed
[X] such applications have been filed as follows.

Prior Foreign Application(s)

9720590.0	GB	26th September 1997	[]	[]
(Number)	(Country)	(day/month/year filed)	Yes	No
9725346.2	GB	28th November 1997	[]	[]
(Number)	(Country)	(day/month/year filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, § 119 (e) of any United States provisional application(s) listed below:

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

_____ (Application Number)	_____ (Filing Date)
-------------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose all information known to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

_____ (Application Serial No.)	_____ (Filing Date)	_____ (patented, pending, abandoned)
-----------------------------------	------------------------	--------------------------------------------

_____ (Application Serial No.)	_____ (Filing Date)	_____ (patented, pending, abandoned)
-----------------------------------	------------------------	--------------------------------------------

I hereby declare all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Jean-Pierre SACHETTO

Inventor's signature _____ (Date)

Residence: Basel, Switzerland

Citizenship: French

Post Office Address: Duchelweiher 13, CH-4051 Basel, Switzerland.

Full name of second joint inventor: William Jeffery SANDBORN

Inventor's signature *William Jeffery Sandborn* May 8, 2000 (Date)

Residence: Minnesota, US

Citizenship: US

Post Office Address: 1132 - 7th Street, S.W. Rochester, Minnesota 55902, USA.

Full name of third joint inventor: William John TREMAINE

Inventor's signature *William J. Tremaine* 05-09-00 (Date)

Residence: Minnesota, US

Citizenship: US

Post Office Address: 625 Memorial Pkwy., S.W. Rochester, Minnesota 55905, USA.

Full name of fourth joint inventor, if any _____

Inventor's signature _____ (Date)

Residence _____

Citizenship _____

Post Office Address _____